title: Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
abstract: SART3-derived peptides applicable to prostate cancer patients with HLA-A3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the HLA-A2 and HLA-A24 alleles. Twenty-nine SART3-derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11, -A31, and -A33) were first screened for their recognizability by immunoglobulin G (IgG) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from HLA-A3 supertype(+) prostate cancer patients. As a result, five SART3 peptides were frequently recognized by IgG, and two of them-SART3 (511-519) and SART3 (734-742)-efficiently induced peptide-specific and cancer-reactive CTLs. Their cytotoxicity toward prostate cancer cells was ascribed to peptide-specific and CD8(+) T cells. These results indicate that these two SART3 peptides could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype(+) prostate cancer patients.
authors.affiliation: Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Minami
authors.forename: Satoko
authors.initials: S
authors.lastname: Matsueda
authors.forename: Hiroko
authors.initials: H
authors.lastname: Takedatsu
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tanaka
authors.forename: Masanori
authors.initials: M
authors.lastname: Noguchi
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Uemura
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
authors.forename: Mamoru
authors.initials: M
authors.lastname: Harada
mesh_terms: D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D005434:Flow Cytometry; D015791:HLA-A3 Antigen / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D010455:Peptides / Q000276:immunology; D011471:Prostatic Neoplasms / Q000097:blood / Q000276:immunology*; D016601:RNA-Binding Proteins / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D015791:HLA-A3 Antigen; D007074:Immunoglobulin G; D010455:Peptides; D016601:RNA-Binding Proteins; C416530:SART3 protein, human